Dependence on Δ9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1290-1295

  Aceto, Mario D ^a,c   Scates, Susan M ^a   Lowe, John A ^b   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; ILLICIT DRUG; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG WITHDRAWAL; EVOKED RESPONSE; HYPOTHERMIA; NONHUMAN; PRIORITY JOURNAL; RAT; STIMULUS RESPONSE; WITHDRAWAL SYNDROME;

ANIMALS; BODY WEIGHT; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

EID: 0030431226     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. ACETO, M., SCATES, S., LOWE, J. AND MARTIN, B.: Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur. J. Pharmacol. 282: R1-R2, 1995a.
2. ACETO, M. D., MARTIN, B. R., SCATES, S. M. AND LOWE, J.: Cannabinoid precipitated withdrawal: induction by the antagonist SR 141716A. FASEB J 9: A403, 1995b.
3. BEARDSLEY, P. M., BALSTER, R. L. AND HARRIS, L. S.: Dependence on tetrahydrocannabinol in rhesus monkeys. J. Pharmacol. Exp. Ther. 239: 311-319, 1986.
4. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277: 568-594.
5. COMPTON, D. R., DEWEY, W. L. AND MARTIN, B. R.: Cannabis dependence and tolerance production. In Addiction Potential of Abused Drugs and Drug Classes, pp 129-147, The Hayworth Press, Inc., Binghampton, NY, 1990.
6. DEWEY, W. L.: Cannabinoid pharmacology. Pharmacol. Rev. 38: 151-178, 1986.
7. FRASER, J. D.: Withdrawal symptoms in cannabis-indica addicts. Lancet 1: 747-748, 1949.
8. 9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacology 71: 201-202, 1980.
9. 9-tetrahydrocannabinol. Psychopharmacology 37: 23-29, 1974.
10. JONES, R. T. AND BENOWITZ, N.: The 30-day trip - Clinical studies of cannabis tolerance and dependence. In Pharmacology of Marihuana, pp 627-642, Raven Press, New York, 1976.
11. JONES, R. T., BENOWITZ, N. AND BACHMAN, J.: Clinical studies of cannabis tolerance and dependence. Ann. N.Y. Acad. Sci. 282: 221-239, 1976.
12. JONES, R. T., BENOWITZ, N. L. AND HERNING, R. I.: Clinical relevance of cannabis tolerance and dependence. J. Clin. Pharmacol. 21: 143S-152S, 1981.
13. 9-tetrahydrocannabinol-tolerant rats. Psychopharmogy, 55: 243-249, 1977.
14. KAYMAKCALAN, S.: Physiological and psychological dependence on THC in rhesus monkeys. In Cannabis and its Derivatives, pp 142-149, Oxford University Press, London, 1972.
15. 9-tetrahydrocannabinol. Acta Med. Turc. Suppl. 1: 5, 1972.
16. LEITE, J. R. AND CARLINI, E. A.: Failure to obtain "cannabis directed behavior" and abstinence behavior in ratschronically treated with cannabis sativa extracts. Psychopharmacology, 36: 133-145, 1974.
17. MCMILLAN, D. E., DEWEY, W. L. AND HARRIS, L. S.: Characteristics of tetrahydrocannabinol tolerance. Ann. N.Y. Acad. Sci. 191: 83-99, 1971.
18. PERTWEE, R. G.: Tolerance to and dependence on psychotropic cannabinoids. In The Biological Bases of Drug Tolerance and Dependence, pp 231-263, Academic Press, New York, 1991.
19. RINALDI-CARMONA, M., BARTH, F., HéAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NÉLIAT, G., CAPUT, D., FERRARA, P., SOUBRIÉ, P., BRELIÈRE, J. C. AND LE FUR, G.: SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350: 240-244, 1994.
20. ROBINS, L. N. AND REGIER, D. A.: Psychiatric Disorders in America. Free Press, MacMillan, New York, 1991.
21. SOUEIF, M. I.: Hashish consumption in Egypt, with special reference to psychosocial aspects. Bull. Narc. 19: 1-12, 1967.
22. STADNICKI, S. W., SCHAEPPI, U., ROSENKRANTZ, U. AND BRAUDE, M. C.: Crude marihuana extract: EEG and behavioral effects of chronic oral administration in rhesus monkeys. Psychopharmacology 37: 225-233, 1974.
23. 9-tetrahydrocannabinol on behavior, body temperature, brain amines and withdrawal-like behaviour in the rat. J. Pharm. Pharmacol. 34: 240-245, 1982.
24. TEIGER, D. G.: Induction of physical dependence on morphine, codeine, and meperidine in the rat by continuous infusion. J. Pharmacol. Exp. Ther. 190: 408-415, 1974.
25. 9-tetrahydrocannabinol precipated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280: R13-R15, 1995.
26. VARGA, K., LAKE, K., MARTIN, B. AND KUNOS, G.: Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 278: 279-283, 1996.
27. 9-tetrahydrocannabinol. Psychopharmacology 68: 261-267, 1980.
28. WALTON, R. P., MARTIN, L. F. AND KELLER, J. H.: The relative activity of various purified products obtained from American grown hashish. J. Pharmacol. Exp. Ther. 62: 239-251, 1937.
29. WILEY, J., BARRETT, R., LOWE, J., BALSTER, R. AND MARTIN, B.: Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34: 669-676, 1995.